Filana Therapeutics, Inc.
FLNA
$1.91
-$0.09-4.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.85M | 3.96M | 5.12M | 13.67M | 20.53M |
| Gross Profit | -3.85M | -3.96M | -5.12M | -13.67M | -20.53M |
| SG&A Expenses | 5.70M | 7.91M | 8.98M | 7.92M | 8.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.55M | 11.86M | 14.09M | 21.59M | 29.49M |
| Operating Income | -9.55M | -11.86M | -14.09M | -21.59M | -29.49M |
| Income Before Tax | -12.54M | -10.81M | -44.22M | -23.40M | -27.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.54M | -10.81M | -44.22M | -23.40M | -27.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.54M | -10.81M | -44.22M | -23.40M | -27.60M |
| EBIT | -9.55M | -11.86M | -14.09M | -21.59M | -29.49M |
| EBITDA | -9.19M | -11.73M | -13.87M | -21.37M | -29.23M |
| EPS Basic | -0.26 | -0.22 | -0.92 | -0.48 | -0.57 |
| Normalized Basic EPS | -0.11 | -0.14 | -0.17 | -0.26 | -0.36 |
| EPS Diluted | -0.26 | -0.22 | -0.92 | -0.48 | -0.57 |
| Normalized Diluted EPS | -0.11 | -0.14 | -0.17 | -0.26 | -0.36 |
| Average Basic Shares Outstanding | 48.31M | 48.31M | 48.31M | 48.26M | 48.10M |
| Average Diluted Shares Outstanding | 48.31M | 48.31M | 48.31M | 48.26M | 48.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |